Cerity Partners
RNAC icon

Cerity Partners’s Cartesian Therapeutics RNAC Stock Holding History

Cerity Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$176K Buy
+16,848
New +$125K ﹤0.01% 3084
2020
Q3 		– Sell
-667
Closed -$57K – 524
2020
Q2 		$57K Buy
+667
New +$60.5K ﹤0.01% 447

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Cerity Partners's RNAC Position: Q2 2026 in Review

Cerity Partners opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 16,848 shares worth $176K. The stake represents ﹤0.01% of the portfolio and ranks #3084 among its holdings. This is a return to the name: Cerity Partners previously reported a position in RNAC as recently as Q2 2020.

Cerity Partners first reported a position in RNAC in Q2 2020 and has held it in 2 quarters since. 94 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Cerity Partners held 16,848 shares of Cartesian Therapeutics worth $176K as of Q2 2026.
  • Cartesian Therapeutics was a new Cerity Partners position in Q2 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3084 holding.
  • Cerity Partners first reported a position in Cartesian Therapeutics in Q2 2020 and has held it in 2 quarters since.
  • 94 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.